How to take OjeMDA (tovorafenib)

Before initiating treatment with OjeMDA (tovorafenib), confirm the presence of BRAF fusions or rearrangements or BRAF V600 mutations; liver function tests, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin, should also be performed.

1. Recommended dose: OjeMDA can be administered as an immediate-release tablet or oral suspension. The recommended dose of OjeMDA based on body surface area (BSA) is 380 mg/m2 orally once a week. (The maximum recommended dose is 600 mg orally once a week.) , with or without food, until disease progression or intolerable toxicity occurs. The recommended dose for patients with BSA<0.3m2 has not yet been determined.

2. Medication management: OjeMDA tablets can be swallowed with water. Do not chew, cut or squeeze.

Oral suspension requires reconstitution: Reconstitute the powder in each supply bottle with exactly 14 mL of room temperature water to form OjeMDA for oral suspension. After reconstitution, each milliliter contains 25mg tovorafenib. Reconstructed product foaming reduces deliverable volume. Each 12 ml bottle of OjeMDA is 300 mg. When the dose is >300 mg, two bottles should be prepared to reach the dose. Divide the dose as evenly as possible between the two bottles (for example, a 325 mg dose would be 6 mL and 7 mL). Administer OjeMDA oral suspension immediately after preparation using the provided oral administration syringe or feeding tube. If OjeMDA for oral suspension is not administered within 15 minutes of preparation, instruct patients to discard.

Medication Adjustment: If a patient misses a dose:3 days or less, take the missed dose as soon as possible and take the next dose on the scheduled date. More than 3 days later, skip the missed dose and take the next dose on the scheduled day. If vomiting occurs immediately after taking a dose, repeat the dose.